grant
Camptothecin analogs as "block and lock" agents for HIV
Organization UNIVERSITY OF CALIFORNIA, SAN DIEGOLocation LA JOLLA, UNITED STATESPosted 24 Feb 2026Deadline 31 Jan 2031
NIHUS FederalResearch GrantFY2026AIDS VirusAIDS/HIVAbscissionAcquired Immune Deficiency Syndrome VirusAcquired Immunodeficiency Syndrome VirusAfter CareAfter-TreatmentAftercareAntibodiesBody TissuesCD4 CellsCD4 Positive T LymphocytesCD4 T cellsCD4 helper T cellCD4 lymphocyteCD4+ T-LymphocyteCD4-Positive LymphocytesCUT&RUNCaliforniaCamptothecin AnalogueCategoriesCell BodyCell FractionationCell LineCell modelCellLineCellsCellular modelChromatinChronicCleavage Targets and Release Using NucleaseCleavage Under Targets and Release Using NucleaseCollaborationsComplexDNADNA Nicking-Closing ProteinDNA Relaxing EnzymeDNA Relaxing ProteinDNA Topoisomerase IDNA Type 1 TopoisomeraseDNA Untwisting EnzymeDNA Untwisting ProteinDNA-Dependent RNA Polymerase IIDeoxyribonucleic AcidDependenceDevelopmentDoseDrugsEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessExcisionExtirpationFlow CytofluorometriesFlow CytofluorometryFlow CytometryFlow MicrofluorimetryFlow MicrofluorometryGene ExpressionGene TranscriptionGenetic TranscriptionGoalsHIVHIV individualsHIV infected individualsHIV infected personsHIV latencyHIV peopleHIV positive individualsHIV positive peopleHIV replicationHIV viral replicationHIV-1 replicationHIV-1 viral replicationHIV-1 virus replicationHIV/AIDSHealthHuman Immunodeficiency VirusesHycamptamineHycamtamineImmune Cell ActivationImmunoglobulin Enhancer-Binding ProteinInflammationKnowledgeLAV-HTLV-IIILength of LifeLongevityLymphadenopathy-Associated VirusLytotoxicityMapsMediatingMedicationMissionModelingModernizationMonitorMorbidityNF-kBNF-kappa BNF-kappaBNFKBNIAIDNational Institute of Allergy and Infectious DiseaseNational Institutes of HealthNon-Polyadenylated RNANuclear ExportNuclear Factor kappa BNuclear RNANuclear Transcription Factor NF-kBNucleosomesOutcomePLWHPWHPharmaceutical PreparationsProductionProteinsProvirus IntegrationProvirusesPublic HealthRNARNA ExpressionRNA Gene ProductsRNA Polymerase BRNA Polymerase IIRNA SplicingRNA StabilityRelaxationRemovalRepressionResearchResidualResidual stateRestRibonucleic AcidSamplingSan FranciscoSplicingStrains Cell LinesSurgical RemovalT-CellsT-LymphocyteT4 CellsT4 LymphocytesTechniquesTestingTherapeuticTimeTissuesTopoisomerase ITopoisomerase I inhibitionTopotecanTranscriptTranscriptionTranscription Factor NF-kBType I DNA TopoisomerasesUnited States National Institutes of HealthUniversitiesValidationViralViral Gene ProductsViral Gene ProteinsViral ProteinsVirusVirus-HIVWorkanalogantiretroviral therapyantiretroviral treatmentasymptomatic HIV infectionburden of diseaseburden of illnesschromatin remodelingchronic HIV infectionco-morbidco-morbiditycomorbiditycultured cell linecytokinecytotoxiccytotoxicityddPCRdevelop therapydevelopmentaldisease burdendroplet digital PCRdroplet digital Polymerase Chain Reactiondroplet-based digital PCRdrug/agentepigeneticallyexperienceexperimentexperimental researchexperimental studyexperimentsfightingflow cytophotometryhistone modificationhuman immunodeficiency virus replicationhuman immunodeficiency virus-1 replicationimmune activationimprovedindividuals infected with HIVindividuals with HIVindividuals with human immunodeficiency virusintervention developmentkappa B Enhancer Binding Proteinlatent HIV infectionlead candidatenew approachesnicking closing enzymenovelnovel approachesnovel strategiesnovel strategynuclear factor kappa betapeople infected with HIVpeople infected with human immunodeficiency viruspeople living with HIVpeople with HIVpeople with human immunodeficiency viruspost treatmentposttranscriptionalpromoterpromotorrelaxing enzymeresectionsubcellular fractionationswivelasetherapy developmentthymus derived lymphocytetreatment developmentuntwisting enzymevalidationsviral RNAvirus RNAvirus protein
Get Agency plan to apply$29.99/mo · 7-day free trial · pipeline · alerts
or
— or —Get email alerts for similar roles
Description preview
Project summary/abstract
Despite effective antiretroviral therapy (ART), people with HIV (PWH) continue to have chronic inflammation
and comorbidities driven by low-level viral transcription from integrated HIV proviruses. Silencing this residual
HIV activity could reduce immune activation and improve long-term health. Our long-term goal is to…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click